OCTOPUS BioSCIENCES

AI-DRIVEN BIOLOGICS DESIGN

Designing proteins, enzymes, and RNA

Using 

foundational AI algorithms, 

diverse biological data, and 

wet-lab validation

We introduce you to 

CIRRINA 

Our AI model 

built for hard-to-target molecules in the brain

Reimagining 

Biologics 

with Cirrina

At Octopus Biosciences, we’ve built Cirrina, a next-generation AI engine that fuses deep molecular understanding with advanced generative design to accelerate the discovery of biologics. 

Trained on multimodal datasets, including structural, sequence, and clinical annotations, Cirrina learns the nuanced language of proteins to generate optimized antibody and peptide therapeutics with unprecedented precision. 

By integrating cutting-edge transformer architectures with constraint-aware search, Cirrina designs candidates that are not only high-affinity and developable but also tailored to complex disease biology.

Accelerating 

Discovery with 

Greater Confidence

While therapeutic development still requires rigorous experimental validation, Cirrina drastically reduces the upfront uncertainty by generating biologics that are computationally optimized for both binding and developability before entering the lab. 

By simulating biophysical constraints—such as solubility, immunogenicity, and epitope accessibility—our platform helps prioritize only the most promising candidates for wet-lab testing. 

This results in a smaller, higher-quality experimental workload and a streamlined path from target selection to validated lead.

Smarter Molecules 

for 

Tougher Diseases

Cirrina was purpose-built to tackle the biologically complex and therapeutically underserved—ranging from neurodegeneration to intracellular protein–protein interactions. 

Our first validation case, focused on tauopathies, demonstrates Cirrina’s ability to rationally design nanobodies against dynamic and aggregation-prone targets. 

By unlocking targets that were previously inaccessible to conventional discovery methods, Nanil is not just accelerating biologics development—we’re expanding the entire therapeutic frontier.